Answers are grounded in this paper and cite their sources.
The Institute of Medicine (IOM) released a groundbreaking 2010 report, Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Key recommendations included a harmonized scientific process and a general framework for biomarker evaluation with three interrelated steps: (1) Analytical validation -- is the biomarker measurement accurate? (2) Qualification -- is the biomarker associated with the clinical endpoint of concern? (3) Utilization -- what is the specific context of the proposed use?
No takes yet. Share an insight, caveat, or question.
Wagner et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: